Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
4
×
life sciences
national blog main
national top stories
boston
clinical trials
san francisco blog main
ally bridge group
alnylam pharmaceuticals
beijing
big data analytics
biobucks
biotech ipos
blackrock
brii bio
brii biosciences
calistoga pharmaceuticals
car-t immunotherapy
casdin capital
checkpoint inhibitors
china
deals
diabetic nephropathy
dyne therapeutics
eventide asset management
fda
focal segmental glomerulosclerosis
gilead sciences
glaxosmithkline
goldfinch bio
gsk
hepatitis b
idelalisib
immuno-oncology
irving investors
jay ghosh
kite pharma
kymriah
What
drug
4
×
million
4
×
medicines
company
genetic
ipo
new
pipeline
raised
therapeutics
adding
adds
alliance
analysis
areas
bets
bio
biosciences
biotech
bio’s
boost
brii
bring
brings
cancer
develop
developing
disease
diseases
disorders
dyne
dyne’s
earlier
employing
expensive
far
gilead
goldfinch
hepatitis
infectious
Language
unset
Current search:
drug
×
million
×
" boston top stories "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango